Patents by Inventor Victoria Smith

Victoria Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LOX AND LOXL2 INHIBITORS AND USES THEREOF
    Publication number: 20130324705
    Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.
    Type: Application
    Filed: May 6, 2013
    Publication date: December 5, 2013
    Applicant: GILEAD BIOLOGICS, INC.
    Inventors: Victoria SMITH, Scott OGG, Peter VAN VLASSELAER, Vivian E. BARRY, Derek MARSHALL, Alison Kay HOLZER, Hector RODRIGUEZ, Miho OYASU, Scott Alan MCCAULEY, Carlos Aurelio GARCIA, Donna Hiroko Tokuoka BIERMANN
  • Antibodies that bind ?2
    Patent number: 8563695
    Abstract: Compositions and methods are provided for the classification, diagnosis, treatment, and prevention of tumors characterized by loss of REST function, expression of ?2, and/or activation of Notch. Further compositions and methods are provided for modulation of cellular processes such as EMT, cell migration, and apoptosis.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: October 22, 2013
    Assignee: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Jing Li, Victoria Smith
  • Catalytic domains from lysyl oxidase and LOXL2
    Patent number: 8512990
    Abstract: Disclosed herein are amino acid sequences, and encoding nucleotide sequences, of isolated catalytic domains of the LOX and LOXL2 proteins from human and mouse. Methods for the preparation and use of these isolated catalytic domains are also provided.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: August 20, 2013
    Assignee: Gilead Biologics, Inc.
    Inventors: Scott McCauley, Victoria Smith
  • Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
    Publication number: 20130149298
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: June 6, 2011
    Publication date: June 13, 2013
    Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebans, JR., Andrew Poison, Victoria Smith
  • LOX and LOXL2 inhibitors and uses thereof
    Patent number: 8461303
    Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: June 11, 2013
    Assignee: Gilead Biologics, Inc.
    Inventors: Victoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko Tokuoka Biermann
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 8398982
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. TAT113 polypeptides comprising the amino acid sequence of SEQ ID NO: 2 are disclosed. Antibodies that bind TAT113 polypeptides, including monoclonal, chimeric, humanized, single chain, and other antibodies, and fragments thereof, are disclosed. Methods of identifying antibodies that bind epitopes bound by such antibodies, including the antibodies produced by hybridoma cell lines disclosed in the application, are provided, wherein the ability of one antibody to block the binding of another antibody to a TAT113 polypeptide indicates that one antibody binds to an epitope bound by the other antibody.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: March 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Patrick Dowd, Gretchen Frantz, Paul Polakis, Victoria Smith, Susan D. Spencer, Thomas D. Wu, Zemin Zhang
  • Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereof
    Publication number: 20130064761
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 10, 2011
    Publication date: March 14, 2013
    Inventors: Belinda Cairns, Ruihuan Chen, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen, Heidi S. Phillips, Paul Polakis, Susan D. Spencer, Victoria Smith, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Patent number: 8388973
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: March 5, 2013
    Assignee: Genentech, Inc.
    Inventors: Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS
    Publication number: 20130017207
    Abstract: Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Applicant: Gilead Biologics, Inc.
    Inventors: Victoria SMITH, Alison Kay Holzer
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20130011402
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: April 13, 2009
    Publication date: January 10, 2013
    Inventors: Patrick Dowd, Gretchen Frantz, Paul Polakis, Victoria Smith, Susan D. Spencer, Thomas D. Wu, Zemin Zhang
  • LYSYL OXIDASE-LIKE 2 ASSAY AND METHODS OF USE THEREOF
    Publication number: 20120309020
    Abstract: The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (LOXL2) polypeptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided.
    Type: Application
    Filed: June 1, 2012
    Publication date: December 6, 2012
    Applicant: Gilead Biologics, Inc.
    Inventors: Victoria Smith, Joanne I. Adamkewicz, Susan K. Lyman, Jason Chien, Xiaoming Li, Lixin Shao, Jeffrey D. Bornstein
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 8278042
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: October 2, 2012
    Assignee: Genentech, Inc.
    Inventors: Belinda Cairns, Ruihuan Chen, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen, Heidi S. Phillips, Paul Polakis, Susan D. Spencer, Victoria Smith, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • LOX AND LOXL2 INHIBITORS AND USES THEREOF
    Publication number: 20120087917
    Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.
    Type: Application
    Filed: August 5, 2011
    Publication date: April 12, 2012
    Inventors: VICTORIA SMITH, VIVIAN E. BARRY, HECTOR RODRIGUEZ, CARLOS AURELIO GARCIA, SCOTT OGG, DEREK MARSHALL, MIHO OYASU, DONNA HIROKO TOKUOKA BIERMANN, PETER VAN VLASSELAER, ALISON KAY HOLZER, SCOTT ALAN MCCAULEY
  • PRO1120 polypeptides
    Patent number: 8106156
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: January 31, 2012
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J Godowski, Austin L Gurney, Victoria Smith, William I Wood
  • N-Myristoyl Transferase Inhibitors
    Publication number: 20110312921
    Abstract: The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.
    Type: Application
    Filed: August 29, 2009
    Publication date: December 22, 2011
    Inventors: Stephen Brand, Paul Wyatt, Stephen Thompson, Victoria Smith, Tracy Bayliss, Justin Harrison, Neil Norcross, Laura Cleghorn, Ian Gilbert, Ruth Brenk
  • Antibodies to PRO7436 polypeptides
    Patent number: 8063186
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: November 22, 2011
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20110274690
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: April 13, 2009
    Publication date: November 10, 2011
    Inventors: Patrick Dowd, Gretchen Frantz, Paul Polakis, Victoria Smith, Susan D. Spencer, Thomas D. Wu, Zemin Zhang
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN
    Publication number: 20110268657
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: December 30, 2010
    Publication date: November 3, 2011
    Inventors: Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, JR., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • IN VITRO SCREENING ASSAYS
    Publication number: 20110207144
    Abstract: Disclosed herein are methods for identifying inhibitors of the catalytic activity of LOXL2 using in vitro assays. In certain embodiments, inhibitors identified by these in vitro assays are effective in inhibiting tumor desmoplasia and fibrosis.
    Type: Application
    Filed: August 20, 2010
    Publication date: August 25, 2011
    Inventors: Derek Marshall, Victoria Smith
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN
    Publication number: 20110206658
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: October 12, 2010
    Publication date: August 25, 2011
    Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebens, JR., Kristi Elkins, Jo-Anne S. Hongo, Jagath Reddy Juntula, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen, Bing Zheng